Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agendia and Ferrer inCode have signed an agreement that will give Ferrer exclusive rights to sell two of Agendia's signature cancer diagnostic services – MammaPrint and CupPrint.
Subscribe to our email newsletter
Under the exclusive distribution agreement, Ferrer has gained rights to sell the tests in Germany, France, Italy, and Portugal, in addition to a current agreement signed in 2007 covering Spain. The companies are also discussing the possibility of future cooperation and expansion into other parts of the world.
MammaPrint is a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, and CupPrint is a gene expression profiling service which offers a fast and reliable method of identifying the primary tumor site in cancer of unknown primary (CUP).
Carlos de Lecea, vice president, international and business development at Ferrer, said: “Both tests provide valuable information that can be used to guide the therapeutic decision making process of oncologists, opening the door to a more personalized treatment for cancer patients.”